peptides for sleep · what the research studies · research use only
Peptides for sleep: which ones the research actually looks at.
If you search 'peptides for sleep,' one compound comes up more than any other with real sleep-lab data behind it: DSIP — delta sleep-inducing peptide. It is a naturally occurring nonapeptide (sequence Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu) first isolated in 1977 by Monnier and Schoenenberger from the cerebral venous blood of sleeping rabbits, and named for its association with delta-wave (deep, slow-wave) sleep. The most direct experimental support is a 1988 PNAS study (Iyer, Marks, Kastin, McCann) reporting that DSIP was tied to slow-wave sleep and sleep-related growth-hormone release in rats; a 2024 Frontiers in Pharmacology paper re-examined a DSIP fusion peptide in a chemically-induced (PCPA) insomnia mouse model. But the honest headline is this: nearly fifty years on, DSIP's own gene has never been found and no specific receptor has been confirmed — a leading review still calls it 'an unresolved riddle.' So the accurate framing of 'peptides for sleep' is 'compounds studied in a sleep context,' not 'proven sleep drugs.' This page reproduces published research as a reference — it is research-use-only and not medical, dosing, or human-use advice. Of the sleep-adjacent research peptides, DSIP is the one Titan actually stocks, as a nasal spray.
DSIP is the canonical 'sleep peptide'
Delta sleep-inducing peptide gets its name from the delta-wave (deep, slow-wave) sleep it was associated with when Monnier and Schoenenberger isolated it in 1977 from the cerebral venous blood of sleeping rabbits. It is a short endogenous nonapeptide (Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu) the body already produces. Among peptides discussed for sleep, it is the one with the longest and most direct sleep-specific research history — which is exactly why it dominates the 'peptides for sleep' conversation.
DSIP side-effect record →The core finding: slow-wave sleep + GH release (1988 PNAS)
The most-cited experimental support is Iyer, Marks, Kastin and McCann (1988, Proc. Natl. Acad. Sci. USA 85:3653-3656), 'Evidence for a role of delta sleep-inducing peptide in slow-wave sleep and sleep-related growth hormone release in the rat.' It ties DSIP to the deep-sleep stage and to the GH pulse that normally accompanies it. This is animal data — real, specific and citeable, but not a human efficacy trial — which is the correct level of confidence to hold.
DSIP half-life →Still being studied in 2026 — but preclinically
Interest is not purely historical: a 2024 Frontiers in Pharmacology paper (Mu et al., doi 10.3389/fphar.2024.1439536) examined a blood-brain-barrier-crossing DSIP fusion peptide in a PCPA-induced insomnia mouse model. Modern work like this keeps DSIP in the research literature, but it remains preclinical (cell and animal models) rather than the large controlled human trials that would establish a clinical sleep effect. 'Actively researched' is true; 'clinically proven for sleep' is not.
Research-use policy →The honest caveat: DSIP is 'an unresolved riddle'
The single most important line on this page: despite nearly five decades of study, DSIP's gene has never been identified and no specific DSIP receptor has been confirmed — independent peptide references summarise the leading scientific review as calling it 'a still unresolved riddle.' Human sleep data is also old, small and inconsistent (1980s-90s Swiss and Dutch sleep labs). So DSIP is genuinely interesting and genuinely under-resolved at the same time. Anyone selling it as a guaranteed sleep fix is overstating what the literature supports.
Dosage reference →Other peptides that come up for sleep
Beyond DSIP, sleep discussions sometimes mention epitalon (a pineal-gland tetrapeptide studied for circadian/melatonin rhythm rather than direct sleep-onset), and calming nasal peptides like selank studied for anxiety that can sit upstream of sleep quality. These are separate research compounds with separate (and generally thinner) sleep evidence — none has DSIP's direct slow-wave-sleep data. Titan stocks DSIP; where a compound isn't stocked, this page won't pretend otherwise.
Nootropic nasal peptides →For a small peptide, identity is the real variable
DSIP is a short, unmodified 9-mer, so a truncated fragment or a mis-synthesised sequence can pass a bare HPLC purity number while being the wrong molecule. That is why identity is confirmed by mass spectrometry against the full expected sequence, not a purity percentage alone. Titan supplies DSIP nasal spray with lot-matched, in-house release documentation (HPLC + ESI-MS identity) available on request — no third-party certificate is claimed; the honest edge is a real, lot-matched in-house release sheet.
How to store peptides →The detail, in plain terms
Peptides-for-sleep research, at a glance.
Points below summarise the published research on DSIP and sleep-adjacent peptides, reproduced as a research reference. The strongest DSIP sleep data is animal/preclinical; human data is small, old and inconsistent; and DSIP's own gene and receptor remain unidentified. Treat this as 'studied in a sleep context,' not 'proven sleep therapy.' Research use only.
- Canonical sleep peptide
- DSIP (delta sleep-inducing peptide), endogenous nonapeptide Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu; isolated 1977 (Monnier & Schoenenberger) from sleeping-rabbit cerebral venous blood.
- Strongest sleep finding
- Linked to slow-wave sleep and sleep-related GH release in the rat — Iyer, Marks, Kastin & McCann, PNAS 85:3653-3656 (1988). Animal data.
- Recent work (2026-era)
- DSIP fusion peptide in a PCPA-induced insomnia mouse model — Mu et al., Front. Pharmacol. 2024 (10.3389/fphar.2024.1439536). Preclinical.
- Human evidence
- Small, old and inconsistent (1980s-90s Swiss/Dutch sleep labs); benefit modest and not reliably reproduced.
- Mechanism status
- Gene never identified; no confirmed specific receptor — reviews still call DSIP 'an unresolved riddle.'
- Sleep-adjacent peptides
- Epitalon (circadian/melatonin rhythm) and selank (anxiety, upstream of sleep quality) come up but have thinner, indirect sleep evidence; not the same as DSIP's slow-wave data.
- Regulatory status
- Not an FDA-approved drug; supplied strictly research-use-only, not for human or animal consumption.
- Identity check
- 9-mer sequence confirmed by mass spectrometry; a truncated fragment can hide behind a purity % alone. Titan: lot-matched in-house HPLC + ESI-MS release sheet on request.
Questions researchers ask
Before you order.
- What peptides are studied for sleep?
- The peptide with the most direct sleep research is DSIP (delta sleep-inducing peptide), a naturally occurring nonapeptide named for its association with delta-wave (deep, slow-wave) sleep and studied since the 1970s. Others that come up in sleep-adjacent discussions include epitalon (studied more for circadian/melatonin rhythm than sleep onset) and calming nasal peptides such as selank (studied for anxiety, which sits upstream of sleep quality). Of these, DSIP has the only direct slow-wave-sleep data. All are research-use-only compounds, and this is a research reference, not medical advice.
- What is DSIP and does it actually help you sleep?
- DSIP is delta sleep-inducing peptide, an endogenous nonapeptide (Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu) first isolated from sleeping rabbits in 1977. Animal research (notably Iyer et al., PNAS 1988) tied it to slow-wave sleep and sleep-related growth-hormone release, and a 2024 mouse-model paper re-examined a DSIP fusion peptide for insomnia. But the honest answer is that human sleep data is small, old and inconsistent, and DSIP's gene and receptor have never been confirmed — a leading review calls it 'an unresolved riddle.' So it is genuinely studied in a sleep context, not a proven sleep drug.
- Which peptide is best for deep or slow-wave sleep?
- In the research literature, DSIP is the peptide specifically associated with deep, slow-wave (delta) sleep — that association is literally what it is named for, and the 1988 PNAS rat study is the anchor finding. No peptide is established as a clinical treatment for improving slow-wave sleep in humans, and DSIP's own human data is limited. It is the most-studied candidate for that specific stage of sleep, which is a different claim from 'proven to work.'
- Is DSIP safe?
- In the small, old controlled human studies that exist, DSIP was repeatedly described as well tolerated with no side effects observed (e.g. Schneider-Helmert 1981), and it is an endogenous peptide the body already makes — both reassuring. But those studies are few, small, mostly intravenous and short, with no large modern safety database and no long-term pharmacovigilance. Read it as 'no adverse-event signal in a limited dataset,' not 'proven safe.' See our dedicated DSIP side-effects reference for detail. Research use only.
- Is DSIP approved for human use for sleep?
- No. DSIP has been studied in humans only in small research settings and is not an FDA-approved drug in the United States. Titan Peptide Lab supplies DSIP nasal spray strictly as a research-use-only reagent for in-vitro laboratory work — not for human or animal consumption, and not as a sleep treatment. The research summarised here is not medical or dosing advice.
- How do I know a sleep peptide like DSIP is the real molecule?
- DSIP is a short, unmodified 9-amino-acid peptide, so a truncated or mis-synthesised sequence can pass a simple HPLC purity number while being the wrong molecule. Genuine identity is confirmed by mass spectrometry against the full expected sequence, not purity alone. Titan provides lot-matched, in-house release documentation (HPLC + ESI-MS identity) on request. We do not claim a third-party certificate; the verifiable edge is a real, lot-matched in-house release sheet.